HUP0402554A2 - Kondenzált heterociklusos szukcinimid-vegyületek, alkalmazásuk, eljárás egyes képviselőik előállítására és a vegyületeket tartalmazó gyógyszerkészítmények - Google Patents
Kondenzált heterociklusos szukcinimid-vegyületek, alkalmazásuk, eljárás egyes képviselőik előállítására és a vegyületeket tartalmazó gyógyszerkészítményekInfo
- Publication number
- HUP0402554A2 HUP0402554A2 HU0402554A HUP0402554A HUP0402554A2 HU P0402554 A2 HUP0402554 A2 HU P0402554A2 HU 0402554 A HU0402554 A HU 0402554A HU P0402554 A HUP0402554 A HU P0402554A HU P0402554 A2 HUP0402554 A2 HU P0402554A2
- Authority
- HU
- Hungary
- Prior art keywords
- cr7r7
- heterocyclic
- group
- optionally substituted
- compounds
- Prior art date
Links
- -1 heterocyclic succinimide compounds Chemical class 0.000 title abstract 6
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 6
- 125000003118 aryl group Chemical group 0.000 abstract 5
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 4
- 125000001475 halogen functional group Chemical group 0.000 abstract 4
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 abstract 3
- 125000004414 alkyl thio group Chemical group 0.000 abstract 3
- HCUOEKSZWPGJIM-YBRHCDHNSA-N (e,2e)-2-hydroxyimino-6-methoxy-4-methyl-5-nitrohex-3-enamide Chemical compound COCC([N+]([O-])=O)\C(C)=C\C(=N/O)\C(N)=O HCUOEKSZWPGJIM-YBRHCDHNSA-N 0.000 abstract 2
- 101100294115 Caenorhabditis elegans nhr-4 gene Proteins 0.000 abstract 2
- 101001109689 Homo sapiens Nuclear receptor subfamily 4 group A member 3 Proteins 0.000 abstract 2
- 101000598781 Homo sapiens Oxidative stress-responsive serine-rich protein 1 Proteins 0.000 abstract 2
- 101000598778 Homo sapiens Protein OSCP1 Proteins 0.000 abstract 2
- 101000613717 Homo sapiens Protein odd-skipped-related 1 Proteins 0.000 abstract 2
- 101001098464 Homo sapiens Serine/threonine-protein kinase OSR1 Proteins 0.000 abstract 2
- 101001067395 Mus musculus Phospholipid scramblase 1 Proteins 0.000 abstract 2
- 102100022673 Nuclear receptor subfamily 4 group A member 3 Human genes 0.000 abstract 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 abstract 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 abstract 2
- 102100037143 Serine/threonine-protein kinase OSR1 Human genes 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- XSXHWVKGUXMUQE-UHFFFAOYSA-N osmium dioxide Inorganic materials O=[Os]=O XSXHWVKGUXMUQE-UHFFFAOYSA-N 0.000 abstract 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 2
- 125000003396 thiol group Chemical group [H]S* 0.000 abstract 2
- 101100519284 Cercospora nicotianae PDX1 gene Proteins 0.000 abstract 1
- 102000034570 NR1 subfamily Human genes 0.000 abstract 1
- 108020001305 NR1 subfamily Proteins 0.000 abstract 1
- 101100277598 Sorghum bicolor DES3 gene Proteins 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 108091008039 hormone receptors Proteins 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 125000003367 polycyclic group Chemical group 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 101150073238 sor1 gene Proteins 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Gynecology & Obstetrics (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Pregnancy & Childbirth (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Nutrition Science (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A találmány az (I) általános képletű vegyületekre, ezek sóira,szolvátjaira, prodrugjaira és sztereoizomerjeire vonatkozik, melyek anukleáris hormon receptor funkció modulátoraiként hatnak. Az (I)általános képletben G jelentése aril- vagy heterociklusos csoport,amely mono- vagy policiklusos és adott esetben szubsztituált; Z1, Z2jelentése O, S, NH vagy NR6; A1 és A2 j elentése CR7 vagy N; Yjelentése J-J'-J", ahol J j elentése (CR7R7') n és n - 0-3, J'jelentése vegyértékkötés vagy 0, S, S=O, SO2S, NH, NR7, C=O, OC=O,NR1C=O, CR7R7', C=CR8R8', R2P=O, R2P=S, R2OP=O, R2NHP=O, OP=OOR2,OP=ONHR2, OP=OR2, OSO2, C=NR7, NHNH, NHNR6, NR6NH, N=N, adott esetbenszubsztituált cikloalkil-, cikloalkenil-, heterociklusos vagyarilcsoport és J" jelentése (CR7R7') n és n=0-3, ahol Y jelentésevegyértékkötéstől eltérő; W jelentése CR7R7'-CR7R7', CR8=CR8', CR7R7'-C=O, C=O-C=O, CR7R7'-C=CH2, C=CH2-C=CH2, CR7R7'-C=NRl, C=NRl-C=NRl,NR9-CR7R7', N=CR8, N=N, NR9-NR9', S-CR7R7', SO-CR7R7', SO2-CR7R7',adott esetben szubsztituált cikloalkil-, cikloalkenil-,heterociklusos, arilcsoport, ahol amikor W jelentése NR9-CR7R7',N=CR8, N=N, NR9-NR9', S-CR7R7', SO-CR7R7', SO2-CR7R7' vagyheterociklusos csoporttól eltérő, akkor J' jelentése kötelezően O, S,S=O, SO2, NH, NR7, OC=O, NR1C=O, OP=OOR2, OP=ONHR2, OSO2, NHNH, NHNR6,NR6NH vagy N=N; Q1 és Q2 jelentése H, adott esetben szubsztituáltalkilalkenil- cikloalkil-, cikloalkenil-, heterocikloalkil-,arilalkil-, alkinil-, aril-, heterociklusos, halo-, CN, R1OC=O, R4C=O,R5R6NC=O, HOCR7R7', nitro-, R1OCH2, R1O, NH2, C=OSR1, SO2Rl vagy NR4R5csoport; L jelentése vegyértékkötés, (CR7R7')n, NH, NR5, NH (CR7R7')nvagy NR5(CR7R7')n, ahol n=0-3; R1 és R1' és R2 jelentése egymástólfüggetlenül H, adott esetben szubsztituált alkil-, alkenil-, alkinil-,cikloalkil-, cikloalkenil-, heterociklusos, cikloalkil-alkil-,cikloalkenilalkil-, heterocikloalkil-, aril-, aril-alkil-csoport; R3és R3' jelentése mint R1-nél megadott, továbbá halo-, CN, hidroxil-amin-, hidroxamid-, alkoxi-, amino-, NR1R2, tiol-, alkil-tio-csoport;R4 és R5 jelentése mint R1-nél megadott, továbbá R1C=O, R1OC=O,R1NHC=O, SO2OR1, SO2Rl vagy SO2NR1R1' csoport; R6 jelentése mint R4 ésR5-nél megadott, továbbá CN, OH OR1; R7 és R7' jelentése mint R1-nélmegadott, továbbá halo, CN, OR4, nitro-, hidroxil-amin-, hidroxil-amid-, amino-, NHR4, NR2R5, NR5R5, NOR1, tiol-, alkil-tio-, HOC=O,R1C=O, R1(C=O)O, R1OC=O, R1NHC=O, NH2C=O, SO2R1, SOR1, PO3R1R1',R1R1'NC=O, C=OSRl, SO2Rl, SO2ORl vagy SO2NR1R1'; R8 és R8' jelentésemint R1-nél megadott, továbbá nitro, halo, CN, OR1, amino-, NHR4,NR2R5, NOR1, alkil-tio-, C=OSR1, R1OC=O, R1C=O, R1NHC=O, R1R1'NC=O,SO2ORl, S=ORl, SO2Rl, PO3R1Rl' vagy SO2NR1R1' csoport: és R9 és R9'jelentése azonos R6 jelentésére megadottakkal. A találmány tárgyatovábbá a vegyületeket tartalmazó gyógyszerkészítmények é
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2511601A | 2001-12-19 | 2001-12-19 | |
| PCT/US2002/040598 WO2003062241A1 (en) | 2001-12-19 | 2002-12-18 | Fused heterocyclic succinimidecompounds and analogs thereof, modulators of nuclear hormone receptor function |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0402554A2 true HUP0402554A2 (hu) | 2005-03-29 |
| HUP0402554A3 HUP0402554A3 (en) | 2009-01-28 |
Family
ID=27609007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0402554A HUP0402554A3 (en) | 2001-12-19 | 2002-12-18 | Condensated heterocyclic succinimide compounds, their use, process for the preparation of some of them and pharmaceutical compositions containing the compounds |
Country Status (31)
| Country | Link |
|---|---|
| EP (1) | EP1458723B1 (hu) |
| JP (1) | JP2005523257A (hu) |
| KR (1) | KR20040086248A (hu) |
| CN (1) | CN1589271A (hu) |
| AR (1) | AR037950A1 (hu) |
| AT (1) | ATE411319T1 (hu) |
| AU (1) | AU2002361785B2 (hu) |
| BR (1) | BR0215281A (hu) |
| CA (1) | CA2471342A1 (hu) |
| CO (1) | CO5640082A2 (hu) |
| DE (1) | DE60229435D1 (hu) |
| DK (1) | DK1458723T3 (hu) |
| ES (1) | ES2314127T3 (hu) |
| GE (1) | GEP20063817B (hu) |
| HR (1) | HRP20040567A2 (hu) |
| HU (1) | HUP0402554A3 (hu) |
| IL (1) | IL162547A0 (hu) |
| IS (1) | IS7324A (hu) |
| MX (1) | MXPA04005876A (hu) |
| NO (1) | NO20043068L (hu) |
| NZ (1) | NZ533471A (hu) |
| PL (1) | PL370904A1 (hu) |
| PT (1) | PT1458723E (hu) |
| RU (1) | RU2330038C2 (hu) |
| SI (1) | SI1458723T1 (hu) |
| TW (1) | TWI263640B (hu) |
| UA (1) | UA78265C2 (hu) |
| UY (1) | UY27595A1 (hu) |
| WO (1) | WO2003062241A1 (hu) |
| YU (1) | YU53604A (hu) |
| ZA (1) | ZA200404812B (hu) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7202264B2 (en) | 2003-01-31 | 2007-04-10 | Isis Pharmaceuticals, Inc. | Supports for oligomer synthesis |
| FR2860793A1 (fr) * | 2003-10-14 | 2005-04-15 | Entomed | Composes derives de norcantharidine, leurs procedes de preparation, les compositions les contenant et leurs utilisations |
| EP2708541B1 (en) * | 2003-11-13 | 2015-01-28 | Isis Pharmaceuticals, Inc. | 5,6-dihydroxy-isoindole derivatives as linkers for oligomer solid phase synthesis |
| US7326728B2 (en) | 2004-01-16 | 2008-02-05 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κβ activity and use thereof |
| US7625921B2 (en) | 2004-01-16 | 2009-12-01 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| US7273881B2 (en) | 2004-01-16 | 2007-09-25 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| US7569689B2 (en) | 2004-01-16 | 2009-08-04 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| US7605264B2 (en) | 2004-01-16 | 2009-10-20 | Bristol-Myers Squibb Company | Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| US7253283B2 (en) | 2004-01-16 | 2007-08-07 | Bristol-Myers Squibb Company | Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| ATE533745T1 (de) * | 2004-03-17 | 2011-12-15 | Pfizer Prod Inc | Neue benzyl(iden)-lactam-derivate |
| US7361654B2 (en) | 2005-01-13 | 2008-04-22 | Bristol-Myers Squibb Co. | Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| US7317024B2 (en) | 2005-01-13 | 2008-01-08 | Bristol-Myers Squibb Co. | Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| US7411071B2 (en) | 2005-01-13 | 2008-08-12 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| US7642273B2 (en) | 2005-01-13 | 2010-01-05 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| ES2349476T3 (es) * | 2005-09-09 | 2011-01-03 | Schering Corporation | Nuevos derivados de 4-ciano, 4-amino y 4-aminometilo de compuestos de pirazolo[1,5-a]piridinas, pirazolo[1,5-c]pirimidinas y 2h-indazol y derivados de 5-ciano, 5-amino y 5-aminometilo de compuestos de imidazo[1,2-a]piridinas e imidazo[1,5-a]pirazinas, como inhibidores de cinasa dependiente de ciclina. |
| ES2452343T3 (es) | 2006-09-29 | 2014-04-01 | Glaxosmithkline Llc | Compuestos de indol sustituidos |
| WO2008157291A2 (en) * | 2007-06-15 | 2008-12-24 | Bristol-Myers Squibb Company | CRYSTALLINE FORMS OF (3Aα, 4β, 5α, 7β, 7Aα)-4-(OCTAHYDRO-5-ETHYLSULFONAMIDO-4,7-DIMETHYL-1,3-DIOXO-4,7-EPOXY-2H-ISOINDOL-2-YL)-2-(TRIFLUOROMETHYL)BENZONITRILE AND METHOD OF PREPARATION |
| CN102459221A (zh) * | 2009-04-30 | 2012-05-16 | 住友化学株式会社 | 噻吩衍生物 |
| US20120135997A1 (en) | 2009-07-17 | 2012-05-31 | Shionogi & Co., Ltd. | Pharmaceutical composition comprising a lactam or benzenesulfonamide compound |
| US20120238533A1 (en) | 2009-09-11 | 2012-09-20 | Bayer Pharma Aktiengesellschaft | (Heteroarylmethyl) Thiohydantoins as anticancer drugs |
| JP5602250B2 (ja) | 2010-01-14 | 2014-10-08 | ノバルティス アーゲー | 副腎ホルモン修飾剤の使用 |
| WO2014111871A1 (en) | 2013-01-17 | 2014-07-24 | Aurigene Discovery Technologies Limited | 4,5-dihydroisoxazole derivatives as nampt inhibitors |
| EP2991994B1 (en) * | 2013-05-01 | 2018-08-15 | Vitae Pharmaceuticals, Inc. | Thiazolopyrrolidine inhibitors of ror-gamma |
| JP6156074B2 (ja) * | 2013-11-08 | 2017-07-05 | 住友化学株式会社 | スクシンイミド化合物及びその用途 |
| EP3527569B1 (en) | 2014-02-03 | 2021-08-25 | Vitae Pharmaceuticals, LLC | Dihydropyrrolopyridine inhibitors of ror-gamma for use in treating drye eye |
| US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| EP3233803B1 (en) * | 2014-12-19 | 2019-01-30 | Aragon Pharmaceuticals, Inc. | Process for the preparation of a diarylthiohydantoin compound |
| US20170327469A1 (en) | 2015-01-20 | 2017-11-16 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| KR102110566B1 (ko) * | 2015-01-20 | 2020-05-13 | 아비나스 오퍼레이션스, 인코포레이티드 | 안드로겐 수용체의 표적화된 분해를 위한 화합물 및 방법 |
| US10301261B2 (en) | 2015-08-05 | 2019-05-28 | Vitae Pharmaceuticals, Llc | Substituted indoles as modulators of ROR-gamma |
| US11008340B2 (en) | 2015-11-20 | 2021-05-18 | Vitae Pharmaceuticals, Llc | Modulators of ROR-gamma |
| TW202220968A (zh) | 2016-01-29 | 2022-06-01 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| ES2922932T3 (es) | 2016-12-29 | 2022-09-21 | Enyo Pharma | Derivados de tiofeno como agentes antivirales |
| MX2020000887A (es) | 2017-07-24 | 2020-07-22 | Vitae Pharmaceuticals Llc | Inhibidores de ror?. |
| WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
| WO2021189051A1 (en) * | 2020-03-20 | 2021-09-23 | University Of Southern California | Androgen receptor regulation by small molecule enantiomers |
| CN114848795B (zh) * | 2021-02-03 | 2023-04-14 | 四川大学 | RORa蛋白及其激动剂在制备抗衰老药物中的应用 |
| WO2023154939A2 (en) * | 2022-02-14 | 2023-08-17 | The Johns Hopkins University | Gcpii inhibition for the treatment of sarcopenia and aging |
| US20240158394A1 (en) | 2022-09-14 | 2024-05-16 | Halia Therapeutics, Inc. | Nek7 inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3320270A (en) * | 1963-10-08 | 1967-05-16 | Tri Kem Corp | Certain 2-acylimidothiazole compounds |
| US3215597A (en) * | 1963-10-30 | 1965-11-02 | Dow Chemical Co | Methods and compositions for use in animal husbandry |
| US3261845A (en) * | 1964-07-14 | 1966-07-19 | Dow Chemical Co | N-phenyl derivatives of 3,6-epoxyhexahydrophthalimide |
| US4892943A (en) * | 1985-10-16 | 1990-01-09 | American Home Products Corporation | Fused bicyclic imides with psychotropic activity |
| JPS63170383A (ja) * | 1987-02-26 | 1988-07-14 | Nippon Zeon Co Ltd | 脂環式ジカルボン酸イミド化合物 |
| ZA908641B (en) * | 1989-10-27 | 1992-06-24 | Du Pont | (n-phthalimidoalkyl)piperidines |
| KR100531967B1 (ko) * | 1996-10-25 | 2005-11-30 | 다이이찌 세이야꾸 가부시기가이샤 | 트리사이클릭 아민 유도체, 이를 포함하는 항균제 및 퀴놀론 화합물의 제조방법 |
| FR2764890B1 (fr) * | 1997-06-24 | 1999-08-27 | Adir | Nouveaux derives chromeniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| JP2002533345A (ja) * | 1998-12-22 | 2002-10-08 | イーライ・リリー・アンド・カンパニー | 置換三環式化合物 |
| CA2413417A1 (en) * | 2000-06-28 | 2002-01-03 | Bristol-Myers Squibb Company | Selective androgen receptor modulators and methods for their identification, design and use |
| UA78686C2 (en) * | 2000-09-19 | 2007-04-25 | Bristol Myers Squibb Co | Fused heterocyclic succinamide compounds and their analogs as modulators of functions of nuclear receptors for hormones |
-
2002
- 2002-12-13 TW TW091136163A patent/TWI263640B/zh active
- 2002-12-18 CN CNA028281063A patent/CN1589271A/zh active Pending
- 2002-12-18 BR BR0215281-9A patent/BR0215281A/pt not_active IP Right Cessation
- 2002-12-18 WO PCT/US2002/040598 patent/WO2003062241A1/en active Application Filing
- 2002-12-18 SI SI200230767T patent/SI1458723T1/sl unknown
- 2002-12-18 HU HU0402554A patent/HUP0402554A3/hu unknown
- 2002-12-18 PT PT02797421T patent/PT1458723E/pt unknown
- 2002-12-18 JP JP2003562118A patent/JP2005523257A/ja not_active Withdrawn
- 2002-12-18 PL PL02370904A patent/PL370904A1/xx not_active Application Discontinuation
- 2002-12-18 DE DE60229435T patent/DE60229435D1/de not_active Expired - Fee Related
- 2002-12-18 KR KR10-2004-7009794A patent/KR20040086248A/ko not_active Application Discontinuation
- 2002-12-18 CA CA002471342A patent/CA2471342A1/en not_active Abandoned
- 2002-12-18 ES ES02797421T patent/ES2314127T3/es not_active Expired - Lifetime
- 2002-12-18 MX MXPA04005876A patent/MXPA04005876A/es active IP Right Grant
- 2002-12-18 RU RU2004122403/04A patent/RU2330038C2/ru not_active IP Right Cessation
- 2002-12-18 AT AT02797421T patent/ATE411319T1/de not_active IP Right Cessation
- 2002-12-18 GE GE5693A patent/GEP20063817B/en unknown
- 2002-12-18 EP EP02797421A patent/EP1458723B1/en not_active Expired - Lifetime
- 2002-12-18 AU AU2002361785A patent/AU2002361785B2/en not_active Ceased
- 2002-12-18 IL IL16254702A patent/IL162547A0/xx unknown
- 2002-12-18 NZ NZ533471A patent/NZ533471A/en unknown
- 2002-12-18 UA UA20040705945A patent/UA78265C2/uk unknown
- 2002-12-18 DK DK02797421T patent/DK1458723T3/da active
- 2002-12-18 YU YU53604A patent/YU53604A/sh unknown
- 2002-12-19 AR ARP020105038A patent/AR037950A1/es unknown
- 2002-12-19 UY UY27595A patent/UY27595A1/es not_active Application Discontinuation
-
2004
- 2004-06-16 CO CO04056353A patent/CO5640082A2/es not_active Application Discontinuation
- 2004-06-17 HR HR20040567A patent/HRP20040567A2/hr not_active Application Discontinuation
- 2004-06-17 ZA ZA200404812A patent/ZA200404812B/en unknown
- 2004-06-18 IS IS7324A patent/IS7324A/is unknown
- 2004-07-16 NO NO20043068A patent/NO20043068L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0402554A2 (hu) | Kondenzált heterociklusos szukcinimid-vegyületek, alkalmazásuk, eljárás egyes képviselőik előállítására és a vegyületeket tartalmazó gyógyszerkészítmények | |
| CA2233285A1 (en) | Pyrazolopyrimidines as crf receptor antagonists | |
| MY119118A (en) | Thiophenopyrimidines | |
| SG49049A1 (en) | 5-(-2-Imidazolinylamino) benzimidazole derivatives their preparation and their use as alpha-2 adrenoceptor agonists | |
| WO2003027076A3 (en) | 1h-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1- antagonistic activity | |
| HUP9802708A2 (hu) | Biciklusos aminszármazékok, intermedierjeik, előállításuk, a vegyületeket hatóanyagként tartalmazó inszekticid, akaricid és nematocid készítmények és alkalmazásuk | |
| DE69131435D1 (de) | Bifunktionale Kupplungsverbindungen, Konjugate und Verfahren zu ihrer Herstellung | |
| WO2007110730A3 (en) | Varenicline standards and impurity controls | |
| YU11501A (sh) | Derivati 4,4,-biarilpiperidina sa aktivnošću na receptor opijata | |
| HUP0104177A2 (hu) | HIV-vírus szaporodását gátló pirimidin-származékok, eljárás az előállításukra, illetve ezeket tartalmazó gyógyászati készítmények | |
| EP1918287A3 (en) | LPA receptor agonists and antagonists and methods of use | |
| HK1097278A1 (en) | Imaging agents | |
| WO2002081453A8 (fr) | Hiohydantoïnes et leur utilisation dans le traitement du diabete | |
| HUP9901074A2 (hu) | Tetrahidropirán és tetrahidrotiopirán aminosavak és ezeket tartalmazó gyógyszerkészítmények | |
| CA2360313A1 (en) | Glucocorticoid receptor modulators | |
| JOP20210259A1 (ar) | مستقبل استروجين يحلل خمير يستهدف التحلل البروتيني | |
| UA84896C2 (ru) | Производные гидронопола как агонисты человеческих рецепторов orl1 | |
| GR3024610T3 (en) | Nitroaniline derivatives and their use as antitumor agents. | |
| Kim et al. | RCANs regulate the convergent roles of NFATc1 in bone homeostasis | |
| MXPA06003374A (es) | Derivados de bencimidazolona y quinazolinona como agonistas en receptores semejantes al receptor opioide 1 de humano. | |
| MA27062A1 (fr) | Compositions pour inhalation, comprenant des 5, 6-dihydro-9h-pyrazolo [3, 4-c]-1, 2, 4-triazolo [4, 3- ] pyridines tricycliques | |
| MX9702203A (es) | Derivados de pirazolil-pirazol substituidos, procedimientos para su preparacion y su uso como agentes con accion herbicida. | |
| WO2006035280A8 (en) | 3,4-dihydroisoquinoline compounds as muscrinic receptor antagonists for the treatment of respiratory, urinary and gastrointestinal diseases | |
| IL113254A0 (en) | Substituted azolone derivatives their preparation and pharmaceutical compositions containing them | |
| HUP9702456A2 (hu) | Fungicid aza-heterocikloalkének, e vegyületeket tartalmazó fungicid szerek, valamint eljárás e vegyületek és fungicid szerek előállítására, továbbá gombakártevők leküzdésére |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA9A | Lapse of provisional patent protection due to relinquishment or protection considered relinquished |